These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 25741152

  • 21. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG, Martin V, Bernasconi B, Del Curto B, Pecciarini L, Uccella S, Pruneri G, Ponzoni M, Mazzucchelli L, Martinelli G, Ferreri AJ, Pinotti G, Assanelli A, Scandurra M, Doglioni C, Zucca E, Capella C, Bertoni F.
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [Abstract] [Full Text] [Related]

  • 22. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
    Chang CC, Kampalath B, Schultz C, Bunyi-Teopengco E, Logan B, Eshoa C, Dincer AP, Perkins SL.
    Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
    [Abstract] [Full Text] [Related]

  • 23. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
    Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY.
    Blood Adv; 2019 Jul 09; 3(13):2013-2021. PubMed ID: 31285189
    [Abstract] [Full Text] [Related]

  • 24. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, Kim CW.
    Histopathology; 2008 Aug 09; 53(2):205-17. PubMed ID: 18752503
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    Kim S, Nam SJ, Kwon D, Kim H, Lee E, Kim TM, Heo DS, Park SH, Kim CW, Jeon YK.
    BMC Cancer; 2016 Jun 10; 16():363. PubMed ID: 27286976
    [Abstract] [Full Text] [Related]

  • 27. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S, Weiss VL, Wang XJ, Desai PA, Hu S, Yin CC, Tang G, Reddy NM, Medeiros LJ, Lin P.
    Am J Surg Pathol; 2016 Feb 10; 40(2):253-61. PubMed ID: 26448193
    [Abstract] [Full Text] [Related]

  • 28. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy.
    Veelken H, Vik Dannheim S, Schulte Moenting J, Martens UM, Finke J, Schmitt-Graeff A.
    Ann Oncol; 2007 May 10; 18(5):931-9. PubMed ID: 17395602
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.
    Li L, Zhang X, Zhang T, Song Z, Hu G, Li W, Li L, Qiu L, Qian Z, Zhou S, Liu X, Feng L, Pan Y, Zhai Q, Meng B, Ren X, Fu K, Wang P, Wang X, Zhang H.
    Clin Lymphoma Myeloma Leuk; 2018 Oct 10; 18(10):e381-e389. PubMed ID: 29983382
    [Abstract] [Full Text] [Related]

  • 31. Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.
    Han YB, Yang JM, Kwon HJ, Lee JO, Lee JS, Paik JH.
    Anticancer Res; 2021 Nov 10; 41(11):5677-5692. PubMed ID: 34732441
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
    Takahashi H, Miura K, Nakagawa M, Sugitani M, Amano Y, Kurita D, Sakagami M, Ohtake S, Uchino Y, Kodaira H, Iriyama N, Kobayashi S, Hojo A, Kobayashi Y, Hirabayashi Y, Kusuda M, Hatta Y, Nakayama T, Takei M.
    Leuk Lymphoma; 2016 Dec 10; 57(12):2784-2790. PubMed ID: 27071312
    [Abstract] [Full Text] [Related]

  • 34. Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.
    Feng Y, Lin J, Liu Y, Tang Y, Zhou Y, Zhong M.
    Int J Exp Pathol; 2019 Feb 10; 100(1):32-40. PubMed ID: 30912195
    [Abstract] [Full Text] [Related]

  • 35. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P.
    J Clin Oncol; 2017 Jan 10; 35(1):24-31. PubMed ID: 28034071
    [Abstract] [Full Text] [Related]

  • 36. Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma.
    Chen F, Liu S, Zhou Y, Shen H, Zuo X.
    Hematology; 2016 Aug 10; 21(7):399-403. PubMed ID: 27077767
    [Abstract] [Full Text] [Related]

  • 37. Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution.
    Zhang S, Wang L, Yu D, Shen Y, Cheng S, Zhang L, Qian Y, Shen Z, Li Q, Zhao W.
    World J Surg Oncol; 2015 Aug 15; 13():246. PubMed ID: 26271948
    [Abstract] [Full Text] [Related]

  • 38. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
    Zhang HW, Chen ZW, He JX, Zheng YP, Han WE, Zhao ZQ, Bai W, Wang JF.
    Zhonghua Zhong Liu Za Zhi; 2013 Feb 15; 35(2):119-23. PubMed ID: 23714666
    [Abstract] [Full Text] [Related]

  • 39. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Schrader AMR, Jansen PM, Vermeer MH, Kleiverda JK, Vermaat JSP, Willemze R.
    Am J Surg Pathol; 2018 Nov 15; 42(11):1488-1494. PubMed ID: 30113335
    [Abstract] [Full Text] [Related]

  • 40. Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.
    Clark Schneider KM, Banks PM, Collie AM, Lanigan CP, Manilich E, Durkin LM, Hill BT, Hsi ED.
    Leuk Lymphoma; 2016 Jul 15; 57(7):1640-8. PubMed ID: 26421520
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.